Dr. Kristi Snell, Ph.D., is a Chief Science Officer, Vice President - Research of the Company. Dr. Snell has more than 20 years of relevant experience and is an industry recognized expert in metabolic engineering of plants and microbes for the production of novel products and increased plant yield. Following her post-doctoral research at MIT on metabolic engineering, Dr. Snell joined Metabolix in 1997 where she has led the plant science research program since its inception. Dr. Snell will be responsible for leading research and development activities, intellectual property development, government grant programs, small scale field tests and larger scale field trials.
Kristi's mailing address filed with the SEC is C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN, MA, 01801.
Over the last 8 years, insiders at Yield10 Bioscience Inc have traded over $1,212,006 worth of Yield10 Bioscience Inc stock and bought 4,271,174 units worth $10,113,836 . The most active insiders traders include Jack W Schuler, Peter N Kellogg, and Joseph H Shaulson. On average, Yield10 Bioscience Inc executives and independent directors trade stock every 107 days with the average trade being worth of $238,638. The most recent stock trade was executed by Jack W Schuler on 20 December 2023, trading 36,000 units of YTEN stock currently worth $7,200.
yield10 bioscience, inc., an agricultural bioscience company, engages in developing disruptive technologies for step-changing improvements in crop yield in the united states and canada. the company, through its trait factory, is involved in developing high value seed traits for the agriculture and food industries. it also has an oilseed development center in saskatchewan, canada. yield10 bioscience, inc. has research agreements with bayer ag to develop traits in soybean; forage genetics international, llc to develop traits in forage sorghum; j. r. simplot company to develop novel traits in potato; and gdm seeds inc. to evaluate yield traits in soybeans. the company was formerly known as metabolix, inc. and changed its name to yield10 bioscience, inc. in january 2017. yield10 bioscience, inc. was founded in 1992 and is headquartered in woburn, massachusetts.
Yield10 Bioscience Inc executives and other stock owners filed with the SEC include: